… Tadwalkar S, Hughes M: Global impact of tyrosine kinase inhibitors on chronic myeloid … :
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid …

… Selection of the next line of treatment after second-generation TKI … the treatment options for
patients resistant to second-generation … on key considerations for treatment decision making. …

… inhibitor, CHMFL-48, that potently inhibits the wild-type BCR-ABL (wt) kinase as well as a
panel of imatinib-resistant … the autophosphorylation of BCR-ABL wt and BCR-ABL mutants in a …

… 6B) that is a second-generation inhibitor used as a second-line treatment for imatinib-resistant
CML not bearing the T315I gatekeeper mutation. The drug is a multikinase inhibitor with …

… are second-generation TKIs with improved efficacy against wild-type and imatinib-resistant …
fold higher potency in vitro against BCR-ABL1 (type 2 inhibition) [35]. It can overcome some …

… AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the
T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009; 16(5):401-412. …

… of optimal response in imatinib resistant and intolerant patients… are higher in the second-line
setting than in front-line [7,8,9]. … BCR-ABL inhibitor approved in Korea for front-line treatment …

… Chronic myeloid leukemia (CML) is caused by the Philadelphia (Ph + ) chromosome … all
first and second generation TKIs. At present, the only clinically available inhibitor that has shown …

… Chronic myeloid leukemia (CML) is a malignant disease of the … of inhibitors and degraders
targeting BCR-ABL for the … effect to most of Imatinib resistant mutants of BCR-ABL as well as …

… kinase inhibitors (TKIs) can be dichotomized into BCR-ABL-… BCR-ABL-dependent
mechanisms encompass BCR-ABL … within the BCR-ABL domain, while BCR-ABL-independent …